Investigating a protein's role in lung disease related to Hermansky-Pudlak Syndrome
Targeting CHI3L1 and its receptors in Hermansky-Pudlak Syndrome-associated lung disease
This study is looking at how a protein called CHI3L1 affects lung health in people with Hermansky-Pudlak Syndrome, especially those dealing with lung issues like pulmonary fibrosis, to find new ways to help protect their lungs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brown University NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project ID | NIH-11037197 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, CHI3L1, and its receptors contribute to lung disease in patients with Hermansky-Pudlak Syndrome (HPS). The study aims to uncover the mechanisms behind pulmonary fibrosis, a serious lung condition that affects individuals with certain genetic mutations associated with HPS. By analyzing the levels of CHI3L1 and its interaction with various cell types, researchers hope to identify potential therapeutic targets that could help manage or prevent lung damage in these patients. The approach includes laboratory studies that examine cellular responses to CHI3L1 and its receptors in the context of lung health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Hermansky-Pudlak Syndrome, particularly those with HPS-1 and HPS-4 subtypes experiencing pulmonary fibrosis.
Not a fit: Patients without Hermansky-Pudlak Syndrome or those not experiencing lung-related complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve lung function and quality of life for patients with Hermansky-Pudlak Syndrome.
How similar studies have performed: Previous studies have shown promising results in targeting CHI3L1 and its receptors in other forms of pulmonary fibrosis, suggesting potential for success in this novel application.
Where this research is happening
Providence, United States
- Brown University — Providence, United States (Active)
Researchers
- Principal investigator: Zhou, Yang — Brown University
- Study coordinator: Zhou, Yang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.